Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?

S G Coulson; V S Kumar; I M Manifold; M Q Hatton; S Ramakrishnan; K S Dunn; O P Purohit; C Bridgewater; R E Coleman

doi:10.1016/j.clon.2010.02.011

Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?

Clin Oncol (R Coll Radiol). 2010 May;22(4):289-93. doi: 10.1016/j.clon.2010.02.011. Epub 2010 Mar 26.

Authors

S G Coulson¹, V S Kumar, I M Manifold, M Q Hatton, S Ramakrishnan, K S Dunn, O P Purohit, C Bridgewater, R E Coleman

Affiliation

¹ Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK.

PMID: 20347281
DOI: 10.1016/j.clon.2010.02.011

Abstract

This review of practice assessed all early breast cancer patients diagnosed over 12 months to determine the frequency of human epidermal growth factor receptor 2 (HER2) positivity and trastuzumab use. The frequency of HER2 positivity in routine practice (185/1319; 14%) was less than expected. A significant proportion of patients (56/185; 30%) did not receive trastuzumab, largely due to concerns about chemotherapy tolerability.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Female
Guideline Adherence
Humans
Receptor, ErbB-2 / analysis
Trastuzumab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Receptor, ErbB-2
Trastuzumab